Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Rapport sur les actions

Capitalisation boursière : US$6.8b

Jazz Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 1/6

Jazz Pharmaceuticals possède un total de capitaux propres de $3.8B et une dette totale de $5.7B, ce qui porte son ratio d'endettement à 151.7%. Son actif total et son passif total sont $11.4B et de $7.6B. L'EBIT de Jazz Pharmaceuticals est $775.6M ce qui fait que son ratio de couverture des intérêts 2.9. Elle dispose de liquidités et de placements à court terme de $2.0B.

Informations clés

151.7%

Ratio d'endettement

US$5.71b

Dette

Ratio de couverture des intérêts2.9x
Argent liquideUS$1.98b
Fonds propresUS$3.76b
Total du passifUS$7.60b
Total des actifsUS$11.36b

Mises à jour récentes de la santé financière

Recent updates

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de JAZZ ( $3.7B ) dépassent ses passifs à court terme ( $1.6B ).

Passif à long terme: Les actifs à court terme de JAZZ ( $3.7B ) ne couvrent pas ses passifs à long terme ( $6.0B ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de JAZZ ( 99% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de JAZZ est passé de 53.7% à 151.7% au cours des 5 dernières années.

Couverture de la dette: La dette de JAZZ n'est pas bien couverte par le flux de trésorerie opérationnel ( 18.8% ).

Couverture des intérêts: Les paiements d'intérêts de JAZZ sur sa dette ne sont pas bien couverts par l'EBIT ( 2.9 x couverture).


Bilan


Découvrir des entreprises saines